Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study

BACKGROUND. Dolutegravir is now recommended for second-line anti-retroviral therapy (ART) in low- and middle-income countries. We compared outcomes with dolutegravir (DTG) versus the previous lopinavir/ritonavir (LPV/r) regimen in South Africa. METHODS. We used routinely collected, de-identified dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Asare, Kwabena, Sookrajh, Yukteshwar, van der Molen, Johan, Khubone, Thokozani, Lewis, Lara, Lessells, Richard J, Naidoo, Kogieleum, Sosibo, Phelelani, van Heerden, Rosemary, Garrett, Nigel, Dorward, Jienchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350157/
https://www.ncbi.nlm.nih.gov/pubmed/37461582
http://dx.doi.org/10.1101/2023.07.07.23292347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350157/
https://www.ncbi.nlm.nih.gov/pubmed/37461582
http://dx.doi.org/10.1101/2023.07.07.23292347

Ejemplares similares